Skip to main content
Clinical Trials/NL-OMON41152
NL-OMON41152
Recruiting
Phase 3

Revascularization with paclitaxel-coated balloon angioplasty versus drug-eluting stenting in acute myocardial infarction - a randomized controlled trial - REVELATIO

Onze Lieve Vrouwe Gasthuis0 sites120 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
acute myocardial infarction
Sponsor
Onze Lieve Vrouwe Gasthuis
Enrollment
120
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Onze Lieve Vrouwe Gasthuis

Eligibility Criteria

Inclusion Criteria

  • All patients presenting with an acute ST\-elevation myocardial infarction and suitable for primary percutaneous coronary intervention(PPCI). The protocol requires visualization, thrombus aspiration and pre\-dilatation of the culprit lesion before inclusion.;Acute myocardial infarction eligible for PPCI:
  • \> 20 min of chest\-pain and at least 1 mm ST\-elevation in at least two contiguous leads, a new left bundle branch block or a true posterior myocardial infarction (confirmed by ECG or echocardiography)
  • reperfusion is expected to be feasible within 12 hours after onset of complaints
  • Infarct related artery eligible for PPCI and:
  • De novo lesion in a native coronary artery
  • Reference\-vessel diameter \>\= 2\.5mm and \<\= 4mm
  • Without severe calcification
  • Without diameter stenosis of \>50% (by visual assessment) after thrombus aspiration and pre\-dilatation.

Exclusion Criteria

  • Age \< 18 years and \> 75 years
  • History of myocardial infarction
  • Known contraindication/resistance for bivalirudin, fondaparinux, heparin, aspirin, prasugrel and/or ticagrelor.
  • Participation in another clinical study, interfering with this protocol
  • Uncertain neurological outcome e.g. resuscitation
  • Intubation/ventilation
  • Cardiogenic shock prior to randomization
  • Known intracranial disease (mass, aneurysm, AVM, hemorrhagic CVA, ischemic CVA/TIA \< 6 months prior to inclusion or ischemic CVA with permanent neurological deficit)
  • Gastro\-intestinal / urinary tract bleeding \< 2 months prior to inclusion
  • Refusal to receive blood transfusion

Outcomes

Primary Outcomes

Not specified

Similar Trials